[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CA2997318A1 - Systemes de traitement de la maladie par application d'une force mecanique par rotation controlee de cellules a l'interieur de nanoparticules - Google Patents

Systemes de traitement de la maladie par application d'une force mecanique par rotation controlee de cellules a l'interieur de nanoparticules Download PDF

Info

Publication number
CA2997318A1
CA2997318A1 CA2997318A CA2997318A CA2997318A1 CA 2997318 A1 CA2997318 A1 CA 2997318A1 CA 2997318 A CA2997318 A CA 2997318A CA 2997318 A CA2997318 A CA 2997318A CA 2997318 A1 CA2997318 A1 CA 2997318A1
Authority
CA
Canada
Prior art keywords
certain embodiments
subject
nanoparticles
particles
target structure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2997318A
Other languages
English (en)
Inventor
Moritz F. KIRCHER
Erik RENSTROM
Martin Koch
Ernst Stetter
Thomas Reis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Memorial Sloan Kettering Cancer Center
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of CA2997318A1 publication Critical patent/CA2997318A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0028—Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5115—Inorganic compounds
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01F—MAGNETS; INDUCTANCES; TRANSFORMERS; SELECTION OF MATERIALS FOR THEIR MAGNETIC PROPERTIES
    • H01F1/00—Magnets or magnetic bodies characterised by the magnetic materials therefor; Selection of materials for their magnetic properties
    • H01F1/44—Magnets or magnetic bodies characterised by the magnetic materials therefor; Selection of materials for their magnetic properties of magnetic liquids, e.g. ferrofluids
    • H01F1/447—Magnets or magnetic bodies characterised by the magnetic materials therefor; Selection of materials for their magnetic properties of magnetic liquids, e.g. ferrofluids characterised by magnetoviscosity, e.g. magnetorheological, magnetothixotropic, magnetodilatant liquids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Cell Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention décrit des systèmes, un appareil, et des procédés d'application de traitement par champ magnétique dynamique (DMF) au mouvement direct, et plus spécifiquement de rotation, de particules magnétiques associées à une structure cible, de sorte qu'une force mécanique soit appliquée à la structure cible. Selon certains modes de réalisation, la présente invention décrit l'utilisation d'un supraconducteur à courant alternatif (ACSC) pour renforcer grandement l'amplitude de champ magnétique de sorte que le champ puisse pénétrer plus profondément dans un corps avec une amplitude suffisante pour commander le mouvement des nanoparticules à l'intérieur d'un volume de travail.
CA2997318A 2015-09-06 2016-09-02 Systemes de traitement de la maladie par application d'une force mecanique par rotation controlee de cellules a l'interieur de nanoparticules Abandoned CA2997318A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562215001P 2015-09-06 2015-09-06
US62/215,001 2015-09-06
PCT/US2016/050090 WO2017040915A1 (fr) 2015-09-06 2016-09-02 Systèmes de traitement de la maladie par application d'une force mécanique par rotation contrôlée de cellules à l'intérieur de nanoparticules

Publications (1)

Publication Number Publication Date
CA2997318A1 true CA2997318A1 (fr) 2017-03-09

Family

ID=57045385

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2997318A Abandoned CA2997318A1 (fr) 2015-09-06 2016-09-02 Systemes de traitement de la maladie par application d'une force mecanique par rotation controlee de cellules a l'interieur de nanoparticules

Country Status (3)

Country Link
EP (1) EP3344334A1 (fr)
CA (1) CA2997318A1 (fr)
WO (1) WO2017040915A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6635791B2 (ja) 2013-02-20 2020-01-29 スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ 広視野ラマン撮像装置および関連方法
US10912947B2 (en) 2014-03-04 2021-02-09 Memorial Sloan Kettering Cancer Center Systems and methods for treatment of disease via application of mechanical force by controlled rotation of nanoparticles inside cells
CA2956210A1 (fr) 2014-07-28 2016-02-04 Memorial Sloan Kettering Cancer Center Nanoparticules de chalcogene metallique (metalloide) en tant que liants universels d'isotopes medicaux
CA2990223A1 (fr) 2015-07-01 2017-01-05 Memorial Sloan Kettering Cancer Center Particules anisotropes, leurs procedes et leurs utilisations
CN109420255A (zh) * 2017-09-01 2019-03-05 温伯格医学物理有限公司 用于对成瘾进行非侵入性治疗的装置和方法
GB2566995B (en) 2017-09-29 2023-01-18 Cotton Mouton Diagnostics Ltd A method of detection

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10020376A1 (de) * 2000-04-26 2001-11-08 Inst Zelltechnologie E V Dynamische Marker
DE112005002270T5 (de) * 2004-09-28 2007-08-30 Osaka University Dreidimensionales Führungssystem und Verfahren, und Arznei-Zuführungssystem
DE102005030986B4 (de) 2005-07-02 2011-06-22 Ernst 64342 Stetter Verwendung rotierender magnetische Nanopartikel
US8293213B2 (en) * 2009-03-12 2012-10-23 Palo Alto Research Center Incorporated Method and apparatus for thrombus removal using magnetic particles
WO2012166796A1 (fr) * 2011-05-31 2012-12-06 Aspen Medisys, Llc Systèmes immunostimulateurs magnétiques et procédés associés

Also Published As

Publication number Publication date
EP3344334A1 (fr) 2018-07-11
WO2017040915A1 (fr) 2017-03-09

Similar Documents

Publication Publication Date Title
US10912947B2 (en) Systems and methods for treatment of disease via application of mechanical force by controlled rotation of nanoparticles inside cells
CA2997318A1 (fr) Systemes de traitement de la maladie par application d'une force mecanique par rotation controlee de cellules a l'interieur de nanoparticules
Huda et al. Potential use of exosomes as diagnostic biomarkers and in targeted drug delivery: progress in clinical and preclinical applications
Ou et al. Cellular senescence in cancer: from mechanisms to detection
Hayashi et al. Differential nanoparticle sequestration by macrophages and scavenger endothelial cells visualized in vivo in real-time and at ultrastructural resolution
Zhang et al. In vivo tracking of multiple tumor exosomes labeled by phospholipid-based bioorthogonal conjugation
Fernandez-Sanchez et al. Mechanical induction of the tumorigenic β-catenin pathway by tumour growth pressure
Qiao et al. Ultrasensitive in vivo detection of primary gastric tumor and lymphatic metastasis using upconversion nanoparticles
Murphy et al. Reversing hypoxia with PLGA-encapsulated manganese dioxide nanoparticles improves natural killer cell response to tumor spheroids
Yi et al. M13 phage-functionalized single-walled carbon nanotubes as nanoprobes for second near-infrared window fluorescence imaging of targeted tumors
Won et al. Oligopeptide complex for targeted non-viral gene delivery to adipocytes
Maiolo et al. Nanomedicine delivery: does protein corona route to the target or off road?
Tsvirkun et al. CT imaging of enzymatic activity in cancer using covalent probes reveal a size-dependent pattern
WO2015134620A1 (fr) Application d'une force mécanique par rotation commandée à distance
Mann et al. Thioaptamer conjugated liposomes for tumor vasculature targeting
Xia et al. In vivo coinstantaneous identification of hepatocellular carcinoma circulating tumor cells by dual-targeting magnetic-fluorescent nanobeads
Gu et al. Nanodiamond-mediated delivery of a G9a inhibitor for hepatocellular carcinoma therapy
Wang et al. Bio-functionalized dense-silica nanoparticles for MR/NIRF imaging of CD146 in gastric cancer
Cesi et al. Transferring intercellular signals and traits between cancer cells: extracellular vesicles as “homing pigeons”
US20130197296A1 (en) Removing Cells from an Organism
Zhang et al. Bioinspired “active” stealth magneto-nanomicelles for theranostics combining efficient MRI and enhanced drug delivery
Son et al. A novel strategy of transferring NIS protein to cells using extracellular vesicles leads to increase in iodine uptake and cytotoxicity
Yezhelyev et al. Inorganic nanoparticles for predictive oncology of breast cancer
Hu et al. Thyroid Cancer Detection by Ultrasound Molecular Imaging with SHP2‐Targeted Perfluorocarbon Nanoparticles
Ishwar et al. Glioblastoma associated natural killer cell EVs generating tumour-specific signatures: noninvasive GBM liquid biopsy with self-functionalized quantum probes

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20220302